Funding for this research was provided by:
National Research Foundation of Korea (NRF-2019R1A2C3004155, 2020M3E5E2037960, 2020M2D9A2092372, 2020M3A9E8024890)
Yonsei University College of Medicine (6-2021-0006)
Received: 29 September 2021
Accepted: 16 November 2021
First Online: 22 November 2021
: Seok-Gu Kang is a scientific advisor for ImmunoMet Therapeutics. The other authors declare no conflict of interest.
: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals followed the ethical standards of the institution or practice at which the studies were conducted.
: Not applicable.